Stay updated on Nivolumab in IDH-Mutant Gliomas Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in IDH-Mutant Gliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in IDH-Mutant Gliomas Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Minor formatting and layout updates across the page; no changes to core study data such as eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T21:03:58.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    37 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    3%
    Check dated 2025-10-06T05:36:21.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.1%
    Check dated 2025-09-29T03:06:51.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.
    Difference
    0.2%
    Check dated 2025-09-14T19:20:37.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T15:49:47.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as various new categories related to proteins and antibodies. Notably, previous terms related to antineoplastic agents and specific medical conditions have been removed.
    Difference
    2%
    Check dated 2025-08-31T11:55:08.000Z thumbnail image

Stay in the know with updates to Nivolumab in IDH-Mutant Gliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in IDH-Mutant Gliomas Clinical Trial page.